Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1999-08-03
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 12, 514 21, 424 851, 424 852, A61K 4505, A61K 3820
Patent
active
059325372
ABSTRACT:
Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
REFERENCES:
patent: 5011778 (1991-04-01), Newman et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5359032 (1994-10-01), Dayer et al.
patent: 5455330 (1995-10-01), Haskill et al.
Carter, et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," Nature 344:633-638 (Apr. 12, 1990).
Cominelli, et al., "Interleukin 1 (IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis," J. Clin. Invest., 86:972-980 (Sep. 1990).
Dinarello, et al., "Multiple Biological Activities of Human Recombinant Interleukin 1, " J. Clin. Invest., 77:1734-1739 (Jun. 1986).
Eisenberg, et al., "Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist," Nature, 343:341-346, (Jan. 25, 1990).
Fanslow, et al., "Regulation of Alloreactivity in Vivo by a Soluble Form of the Interleukin-1 Receptor, " Science, 248:739-742, (May 1990).
Gosset, et al., "Production of an Interleukin-1 Inhibitor Factor by Human Alveolar Macrophages from Normals and Allergic Asthmatic Patients," Am. Rev. Respir. Dis., 138:40-46 (1988).
Gershenwald, et al., "Interleukin 1 receptor blockade attenuates the host inflammatory response," Proc. Natl. Acad. Sci. USA, 87:4966-4970 (Jul. 1990).
Hannum, et al., "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," Nature, 343:336-339 (Jan. 25, 1990).
Maliszewski, et al., "Cytokine Receptors and B Cell Functions--1. Recombinant Soluble Receptors Specifically Inhibit IL-1- and IL-4-Induced B Cell Activities in Vitro, " The Journal of Immunology, 144:3028-3033, No. 8 (Apr. 15, 1990).
Oppenheim, et al., "There is More Than One Interleukin 1," Immunology Today, Reviews, 7:45-56 No. 2 (1986).
Palaszynski, "Synthetic C-Terminal Peptide of IL-1 functions as a Binding Domain As Well As An Antagonist For The IL-1 Receptor," Biochemical and Biophysical Research Communications, 147:204-211, No. 1 (Aug. 31, 1987).
Seckinger, et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1.alpha. and 1.beta. But Not Tumor Necrosis Factor .alpha.," The Journal of Immunology, 139:1541-1545, No. 5 (Sep. 1, 1987).
Simpson, et al., "Reduction of Experimental Canine Myocardial Reperfusion Injury by a Monoclonal Antibody (Anti-Mol, Anti-CD11b) That Inhibits Leukocyte Adhesion," J. Clin. Invest., 81:624-629 (Feb. 1988).
Dorland's Illustrated Medical Dictionary, 24th Ed., W.B. Saunders Company, Philadelphia, PA., p. 760, defining "ischemia," (1965).
Vedder, et al., "A Monoclonal Antibody to he Adherence-promoting Leukocyte Glycoprotein, CD18, Reduces Organ Injury and Improves Survival from Hemorrhagic Shock and Resuscitation in Rabbits," J. Clin. Invest., 81:939-944 (1988).
Cotran, et al., "Induction and Detection of a Human Endothelial Activation Antigen In Vivo," Brief Definitive Report, J. Exp. Med. 164: 661-666, (Aug. 1986).
Buchan, et al., "Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1.alpha.," Clin. Exp. Immunol. 73:449-455 (Mar. 1988).
Haskill John S.
Ralph Peter
Watson Joanna Mizen
Blackburn Robert P.
Chiron Corporation
Draper Garnette D.
Pochopien Donald J.
Savereide Paul B.
LandOfFree
Method for attenuating a cellular response to IL-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for attenuating a cellular response to IL-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for attenuating a cellular response to IL-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-849391